Omalizumab

Specification

• Cat#: THA-0008
• Product Name: Omalizumab
• Description: Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy.
• Sequences: Not Available
• Molecular Weight: 149000.0 Da (approximate)
• Introduction: Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reactions. By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells. Omalizumab was first approved in the US in 2003 and in Europe in 2005. It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria, and asthma.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Liquid
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: Omalizumab decreases free IgE levels in serum in a dose-dependent manner. Serum total IgE levels, accounting for bound and unbound IgE, increased after the first dose of omalizumab due to the formation of drug:IgE complexes, which have a slower elimination rate compared with free IgE. At 16 weeks after the first dose, average total IgE levels in serum were five-fold higher compared to pre-treatment levels in standard assays. Drug effects on IgE levels are reversible upon drug discontinuation, with no observed rebound in IgE levels after drug washout. Total IgE levels did not return to pre-treatment levels for up to one year after discontinuation of omalizumab.
• Targets: Immunoglobulin heavy constant epsilon